NasdaqGS:CAPRBiotechs
Capricor Therapeutics (CAPR) Stock Looks Overvalued As Its 442% Run Draws Focus
Capricor Therapeutics has delivered a very large 3 year gain, yet the stock now screens as overvalued on market multiples and earns a mixed valuation score, so the recent pullback raises questions about how much of the story is already reflected in the price.
Capricor Therapeutics has returned about 4.4x over the past 3 years, which puts extra focus on whether the current share price leaves enough room for disappointment.
The upcoming FDA review and PDUFA decision for Deramiocel can be a key...